OpenURL Connection Search

Select item for more details and to access through your institution.

Lidocaine down-regulates nuclear factor-κB signalling and inhibits cytokine production and T cell proliferation.
Published in:
Clinical & Experimental Immunology, 2008, v. 152, n. 2, p. 320, doi. 10.1111/j.1365-2249.2008.03636.x
By:
- Lahat, A.;
- Horin, S. B.;
- Lang, A.;
- Fudim, E.;
- Picard, O.;
- Chowers, Y.
Publication type:
Article
Soluble Syndecan-1: A Novel Biomarker of Small Bowel Mucosal Damage in Children with Celiac Disease.
Published in:
2017
By:
- Yablecovitch, D.;
- Oren, A.;
- Ben-Horin, S.;
- Fudim, E.;
- Eliakim, R.;
- Saker, T.;
- Konikoff, F.;
- Kopylov, U.;
- Matthias, T.;
- Lerner, A.;
- Konikoff, F M
Publication type:
journal article
Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti‐tumour necrosis factor.
Published in:
Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 8, p. 1117, doi. 10.1111/apt.14567
By:
- Ben‐Horin, S.;
- Ungar, B.;
- Kopylov, U.;
- Lahat, A.;
- Yavzori, M.;
- Fudim, E.;
- Picard, O.;
- Peled, Y.;
- Eliakim, R.;
- Del Tedesco, E.;
- Paul, S.;
- Roblin, X.
Publication type:
Article
Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.
Published in:
Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 2, p. 212, doi. 10.1111/apt.14410
By:
- Bar‐Yoseph, H.;
- Levhar, N.;
- Selinger, L.;
- Manor, U.;
- Yavzori, M.;
- Picard, O.;
- Fudim, E.;
- Kopylov, U.;
- Eliakim, R.;
- Ben‐Horin, S.;
- Chowers, Y.;
- Ungar, B.
Publication type:
Article
Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab.
Published in:
Alimentary Pharmacology & Therapeutics, 2017, v. 45, n. 2, p. 276, doi. 10.1111/apt.13862
By:
- Ungar, B.;
- Kopylov, U.;
- Engel, T.;
- Yavzori, M.;
- Fudim, E.;
- Picard, O.;
- Lang, A.;
- Williet, N.;
- Paul, S.;
- Chowers, Y.;
- Bar‐Gil Shitrit, A.;
- Eliakim, R.;
- Ben‐Horin, S.;
- Roblin, X.
Publication type:
Article
Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis.
Published in:
Alimentary Pharmacology & Therapeutics, 2016, v. 43, n. 12, p. 1293, doi. 10.1111/apt.13631
By:
- Ungar, B.;
- Mazor, Y.;
- Weisshof, R.;
- Yanai, H.;
- Ron, Y.;
- Goren, I.;
- Waizbard, A.;
- Yavzori, M.;
- Fudim, E.;
- Picard, O.;
- Loebstein, R.;
- Kopylov, U.;
- Dotan, I.;
- Chowers, Y.;
- Eliakim, R.;
- Ben‐Horin, S.
Publication type:
Article
The decline of anti-drug antibody titres after discontinuation of anti- TNFs: implications for predicting re-induction outcome in IBD.
Published in:
Alimentary Pharmacology & Therapeutics, 2012, v. 35, n. 6, p. 714, doi. 10.1111/j.1365-2036.2012.04997.x
By:
- Ben‐Horin, S.;
- Mazor, Y.;
- Yanai, H.;
- Ron, Y.;
- Kopylov, U.;
- Yavzori, M.;
- Picard, O.;
- Fudim, E.;
- Maor, Y.;
- Lahat, A.;
- Coscas, D.;
- Eliakim, R.;
- Dotan, I.;
- Chowers, Y.
Publication type:
Article

Found: 7

Lidocaine down-regulates nuclear factor-κB signalling and inhibits cytokine production and T cell proliferation.

Soluble Syndecan-1: A Novel Biomarker of Small Bowel Mucosal Damage in Children with Celiac Disease.

Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti‐tumour necrosis factor.

Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.

Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab.

Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis.

The decline of anti-drug antibody titres after discontinuation of anti- TNFs: implications for predicting re-induction outcome in IBD.